Literature DB >> 17515874

End-tidal carbon monoxide levels in prematurely born infants developing bronchopulmonary dysplasia.

Caroline May1, Sabina Patel, Janet Peacock, Anthony Milner, Gerrard F Rafferty, Anne Greenough.   

Abstract

Bronchopulmonary dysplasia (BPD) is associated with an early inflammatory response that persists after the first week of life. Inflammatory mediators can induce hemoxygenase-1 with a consequent increase in carbon monoxide (CO) production. End-tidal CO (ETCO) levels would be elevated in infants developing BPD. Serial measurements of ETCO levels were attempted on d 3, 5, 7, 14, 21, and 28 in 50 prematurely born infants (median gestational age 29 wk). Fourteen infants developed BPD [oxygen dependent beyond 36 wk post-menstrual age (PMA)] and had higher ETCO levels compared with the rest of the cohort on d 7, 14, 21, and 28. On d 14, the mean (SD) ETCO levels of the BPD group were 3.19 (1.11) ppm and 1.43 (0.61) ppm in the non-BPD group (p<0.001). An ETCO level on d 14>2.15 ppm had a sensitivity of 80% and specificity of 92% in predicting oxygen dependency at 36 wk PMA. Measurement of ETCO levels in prematurely born infants may be useful in the prediction of BPD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17515874     DOI: 10.1203/pdr.0b013e3180332bfe

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  10 in total

1.  Early end-tidal carbon monoxide levels and neurodevelopmental outcome at 3 years 6 months of age in preterm infants.

Authors:  Cornelie A Blok; Tannette G Krediet; Annemiek Kavelaars; Corine Koopman-Esseboom; Hendrik J Vreman; Frank Van Bel
Journal:  Dev Med Child Neurol       Date:  2011-09-20       Impact factor: 5.449

Review 2.  Early biomarkers as predictors for bronchopulmonary dysplasia in preterm infants: a systematic review.

Authors:  Zhi-Qun Zhang; Xian-Mei Huang; Hui Lu
Journal:  Eur J Pediatr       Date:  2013-09-01       Impact factor: 3.183

Review 3.  The role of gasotransmitters in neonatal physiology.

Authors:  Taiming Liu; George T Mukosera; Arlin B Blood
Journal:  Nitric Oxide       Date:  2019-12-20       Impact factor: 4.427

Review 4.  Use of carbon monoxide as a therapeutic agent: promises and challenges.

Authors:  Roberta Foresti; Mohamed G Bani-Hani; Roberto Motterlini
Journal:  Intensive Care Med       Date:  2008-02-20       Impact factor: 17.440

5.  Dermal carbon monoxide excretion in neonatal rats during light exposure.

Authors:  Hendrik J Vreman; Yuri Knauer; Ronald J Wong; Miu-Lan Chan; David K Stevenson
Journal:  Pediatr Res       Date:  2009-07       Impact factor: 3.756

6.  Carboxyhemoglobin Formation in Preterm Infants Is Related to the Subsequent Development of Bronchopulmonary Dysplasia.

Authors:  Shuko Tokuriki; Takashi Okuno; Genrei Ohta; Yusei Ohshima
Journal:  Dis Markers       Date:  2015-07-29       Impact factor: 3.434

7.  Correlation of serum KL-6 and CC16 levels with neurodevelopmental outcome in premature infants at 12 months corrected age.

Authors:  Zhiqun Zhang; Hui Lu; Yunxia Zhu; Junhua Xiang; Xianmei Huang
Journal:  Sci Rep       Date:  2015-01-29       Impact factor: 4.379

8.  Exhaled carbon monoxide levels in infants and toddlers with episodic asthma.

Authors:  Yoichiro Ohara; Takahiro Ohara; Koichi Hashimoto; Mitsuaki Hosoya
Journal:  Fukushima J Med Sci       Date:  2020-06-27

9.  Unmyelinated white matter loss in the preterm brain is associated with early increased levels of end-tidal carbon monoxide.

Authors:  Cornelie A Blok; Karina J Kersbergen; Niek E van der Aa; Britt J van Kooij; Petronella Anbeek; Ivana Isgum; Linda S de Vries; Tannette G Krediet; Floris Groenendaal; Hendrik J Vreman; Frank van Bel; Manon J Benders
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

Review 10.  Biomarkers for Bronchopulmonary Dysplasia in the Preterm Infant.

Authors:  Lidys Rivera; Roopa Siddaiah; Christiana Oji-Mmuo; Gabriela R Silveyra; Patricia Silveyra
Journal:  Front Pediatr       Date:  2016-03-31       Impact factor: 3.418

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.